Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry [1] Core Insights - The pharmaceutical sector has shown resilience, with the innovative drug segment leading a rebound, driven by positive industry dynamics and market sentiment [7][10] - The report emphasizes the potential for continued growth in innovative drugs, supported by favorable government policies and strong performance in recent financial disclosures from biotech and biopharma companies [7][10] - The long-term care insurance (LTCI) policy in China is expected to accelerate the development of the elderly care industry, drawing parallels with Japan's successful model [10][23] Summary by Sections 1. Long-term Care Insurance and Elderly Care Industry - The Chinese government aims to establish a long-term care insurance system within three years, initially covering employees, retirees, and gradually including unemployed rural residents [10] - The LTCI system is designed to alleviate the financial burden on families and improve care for the elderly, with a focus on home and community care [10][23] - Investment opportunities in the elderly care sector include home medical devices, rehabilitation equipment, and elderly care institutions [23] 2. Pharmaceutical Market Review and Hotspot Tracking - The pharmaceutical index increased by 1.56% during the week of March 23-27, outperforming the ChiNext and CSI 300 indices [24] - The overall trading volume for pharmaceuticals was 449.11 billion yuan, accounting for 4.28% of the total market, below the historical average of 7.06% [46] - The report highlights the strong performance of innovative drugs, with companies like Meinuohua and Wanbangde leading the gains [49] 3. Investment Recommendations - The report suggests focusing on companies involved in the overseas big pharma BD 2.0 phase, such as Kelun Pharmaceutical and Xinlitai, as well as small and mid-cap biotech firms with innovative technologies [7][23] - It also recommends monitoring the supply chain and technology sectors, including CROs and CDMOs, as they are expected to benefit from ongoing industry trends [7][23]

Investment Rating - The report maintains a "Buy" rating for the pharmaceutical and biotechnology industry, focusing on brain-machine interface technologies and companies like Microinvasive Brain Science, Xiangyu Medical, and Aipeng Medical [1]. Core Insights - The report highlights significant advancements in the brain-machine interface sector, particularly the approval of the first product, which marks a pivotal moment for the industry. This approval is expected to facilitate further commercialization and development within the sector [18][24]. - The report ranks sub-industries in the following order of attractiveness: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies. It emphasizes high elasticity in innovative drugs, especially in small nucleic acid therapies, and high dividend yields in traditional Chinese medicine and pharmacies [3][11]. Summary by Sections Industry Trends - The A-share pharmaceutical index has shown a slight decline of -0.22% this week and -0.13% year-to-date, underperforming the CSI 300 index by -0.41% and -0.97% respectively. The Hang Seng Biotechnology Index has also decreased by -4.00% this week [11]. - Notable stock performances include Yingke Medical (+35.18%), Zhonghong Medical (+25.26%), and *ST Jingfeng (+15.64%) for gains, while Yifang Biological (-11.59%) and Huakang Clean (-10.79%) faced significant losses [11]. R&D Progress and Company Dynamics - The report details the approval of several innovative drugs, including HSK31679 for non-alcoholic fatty liver disease and the GLP-1 receptor agonist Enoglutide, which has received approval in China [2][3]. - Companies to watch include: - From the PD1 PLUS perspective: Sanofi Biopharma, Kangfang Biopharma, and others - From the ADC perspective: Ying'en Biopharma and others - From the small nucleic acid perspective: Frontier Biopharma and others - From the CXO and upstream research services perspective: WuXi AppTec and others [3][14]. Brain-Machine Interface Developments - The report emphasizes the approval of the NEO brain-machine interface by the National Medical Products Administration, which is the first of its kind globally. This product is designed for patients with cervical spinal cord injuries and offers a minimally invasive solution with high signal quality and low tissue damage [18][20]. - The approval is seen as a breakthrough that sets a standard for future products in the brain-machine interface space, supported by government policies and funding initiatives aimed at fostering industry growth [24][25].

河南翔宇医疗设备股份有限公司 简式权益变动报告书 上市公司名称：河南翔宇医疗设备股份有限公司 股票上市地点：上海证券交易所 股票简称：翔宇医疗 股票代码：688626 信息披露义务人：安阳启旭贸易咨询服务中心（有限合伙） 住所或通讯地址：河南省安阳市内黄县县城西环路中段东侧 执行事务合伙人：郭军玲 一致行动人 1：河南翔宇健康产业管理有限公司 住所或通讯地址：内黄县城帝喾大道中段西侧 法定代表人：郭军玲 一致行动人 2：何永正 住所或通讯地址：河南省安阳市内黄县帝喾大道中段 一致行动人 3：郭军玲 住所或通讯地址：河南省安阳市内黄县帝喾大道中段 股份变动性质：减少股份（减持） 简式权益变动报告书签署日期：2026 年 3 月 11 日 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购办法》"）、《公开发行证券公司信息 披露内容与格式准则第 15 号——权益变动报告书》（以下简称"准则 15 号"）及 相关的法律、法规编写本报告书。 四、本次权益变动是根据本报告所载明的资料进行的。信息披露义务人没有 委托或者授权其他任何人 ...

安阳启旭贸易咨询服务中心（有限合伙）保证向本公司提供的信息真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息 一致。 证券代码：688626 证券简称：翔宇医疗 公告编号：2026-006 河南翔宇医疗设备股份有限公司 关于股东权益变动触及 5%刻度的提示性公告 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | ☑控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他______________（请注明） | 2.信息披露义务人信息 | | | 一致行动人名称 投资者身份 统一社会信用代码 河南翔宇健康产业管 理有限公司 ☑ 控股股东/实控人 □ 控股股东/实控人的一致 行动人 □ 其他直接持股股东 ☑ 91410527MA3XE23G4R □ 不适用 何永正 ☑ 控股股东/实控人 □ 控股股东/实控人的一致 行动人 □ 其他 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2026-005 河南翔宇医疗设备股份有限公司 关于股东权益变动触及 1%刻度的提示性公告 安阳启旭贸易咨询服务中心（有限合伙）保证向本公司提供的信息真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息 一致。 二、 权益变动触及 1%刻度的基本情况 河南翔宇医疗设备股份有限公司（以下简称"公司"）股东安阳启旭贸易咨 询服务中心（有限合伙）及其一致行动人河南翔宇健康产业管理有限公司、何永 正、郭军玲合计持有公司股份 108,146,200 股，占公司总股本的比例为 67.59%。 2026 年 2 月 11 日至 2026 年 3 月 4 日，信息披露义务人通过集中竞价交易方式 减持公司股份 696,896 股、通过大宗交易方式减持公司股份 1,601,835 股，合计 减持公司股份 2,298,731 股，占公司总股本的比例为 1.44%。该次权益变动后， 安阳启旭贸易咨询服务中心（有限合伙）及其一致行动人河南翔宇健康产业管理 有限公司、何永正、郭军玲合计持有公司股份数量由 108,146 ...

证券代码：688626 证券简称：翔宇医疗 公告编号：2026-004 河南翔宇医疗设备股份有限公司 关于股东权益变动触及 1%刻度的提示性公告 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | ☑控股股东/实际控制人及其一致行动人 | | --- | --- | | | □其他 5%以上大股东及其一致行动人 | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他______________（请注明） | 2.信息披露义务人信息 | | | | | □ | 控股股东/实控人 | | | | --- | --- | --- | --- | --- | | 安阳启旭贸易咨询服 务中心（有限合伙） | ☑ | 控股股东/实控人的一致 | ☑ | 91410500MA44M3B22H | | | 行动人 | | □ | 不适用 | | | □ | 其他直接持股股东 | | | 安阳启旭贸易咨询服务中心（有限合伙）保证向本公司提供的信息真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事 ...

Core Viewpoint - The company reported a stable revenue growth of 3.26% in 2025, reaching 768 million yuan, but experienced a significant decline in net profit by 23.55%, indicating a divergence between revenue and profit due to cost structure issues [1][2]. Financial Performance - The total revenue for the reporting period was 768 million yuan, compared to 744 million yuan in the previous year, reflecting a growth of 3.26% [8]. - Operating profit decreased by 28.98% to 77 million yuan, while total profit fell by 30.25% to 74.79 million yuan [8]. - The net profit attributable to the parent company was 79 million yuan, down from 102 million yuan, marking a decline of 23.55% [8]. - The net profit after deducting non-recurring items dropped by 34.48%, indicating a more pronounced pressure on the core profitability [6][8]. - Basic earnings per share decreased by 22.73% to 0.51 yuan, and the weighted average return on equity fell by 1.32 percentage points to 3.70% [8]. Cost Structure and Profitability - The decline in profit is primarily attributed to increased research and development (R&D) expenses and higher depreciation and amortization costs [4][5]. - The company has been investing in high-end rehabilitation technology and talent, leading to a rise in overall expenses [4]. - As construction projects from previous investments come into operation, depreciation and amortization expenses have significantly increased, exerting continuous pressure on profits [5]. Asset and Equity Growth - As of the end of 2025, total assets reached 3.27 billion yuan, an increase of 11.64% year-on-year, while equity attributable to the parent company grew by 1.54% to 2.07 billion yuan [9]. - The growth in assets is primarily driven by ongoing construction and investment, indicating that the company is still in an expansion phase [9]. Cash Flow Analysis - The net operating cash flow was 178.59 million yuan, showing a decline compared to 2023 but remaining positive overall [10]. - Investment cash flow was negative at -275.76 million yuan, indicating continued investment efforts, while financing cash flow turned positive at 148.38 million yuan, providing funding support for expansion [16]. Strategic Outlook - The company is currently in a phase of "sustained investment and capability building," rather than a profit release phase [11]. - The rehabilitation medical equipment sector is driven by demographic trends and healthcare system development, suggesting strong long-term demand [12]. - The company is transitioning from "scale expansion" to "capability accumulation," with short-term performance fluctuations being a result of strategic investments [13]. Future Considerations - Key observation points include the ability to convert investments into product strength and market share, which will determine if the company can re-enter a profit release cycle [15].

Group 1 - The core viewpoint of the article is that Xiangyu Medical reported its 2025 annual performance, showing a slight increase in revenue but a significant decrease in net profit [2] - The company achieved a total operating revenue of 767.74 million yuan in 2025, representing a year-on-year growth of 3.26% [2] - The net profit attributable to the parent company was 78.69 million yuan, which reflects a year-on-year decrease of 23.55% [2]

Core Viewpoint - Xiangyu Medical (688626.SH) reported a slight increase in total operating revenue for the fiscal year 2025, but experienced a significant decline in net profit attributable to the parent company [1] Financial Performance - The company achieved total operating revenue of 767.75 million yuan, representing a year-on-year growth of 3.26% [1] - The net profit attributable to the parent company was 78.70 million yuan, reflecting a year-on-year decrease of 23.55% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 58.95 million yuan, down 34.48% year-on-year [1] Operational Insights - The company focused on technological innovation and improving operational efficiency, which contributed to the slight revenue growth compared to the previous year [1] - There was an increase in expenses related to the recruitment of high-end rehabilitation technology talent, as well as rising salaries for research personnel [1] - The company also faced increased depreciation and amortization costs due to the ongoing use of construction projects, which negatively impacted net profit [1]

Financial Performance - Total revenue for 2025 reached 767.75 million CNY, a year-on-year increase of 3.26%[3] - Net profit attributable to shareholders decreased by 23.55% to 78.70 million CNY[3] - Net profit excluding non-recurring gains and losses fell by 34.48% to 58.95 million CNY[3] - Basic earnings per share decreased by 22.73% to 0.51 CNY[3] - The weighted average return on equity decreased by 1.32 percentage points to 3.70%[3] Assets and Equity - Total assets increased by 11.64% to 3,268.63 million CNY[3] - Shareholders' equity attributable to the parent company rose by 1.54% to 2,070.10 million CNY[3] Operational Factors - The decline in net profit was primarily due to increased R&D expenses and depreciation costs[6] - The company continues to focus on technological innovation and improving operational efficiency[5] Report Accuracy - There are no significant uncertainties affecting the accuracy of the performance report[7]